Accession Number:



A Simple System for the Early Detection of Breast Cancer

Descriptive Note:

Technical Report,01 Jul 2015,30 Jun 2016

Corporate Author:

Arizona State University Tempe United States

Personal Author(s):

Report Date:


Pagination or Media Count:



We invented the immunosignature technology IMS as a simple, universal diagnostic. Our goal has been to apply it to the early detection of disease through simple health monitoring. In the project funded here we proposed to determine if IMS could be applied to the early detection of breast cancer. It is well established that detection of breast cancer at Stage I or earlier has a 100 5 year survival rate. We proposed to use the prospectively collected, NCI-PLCO samples for this project. 150,000 people were enrolled over 8 years 1993-2001 and half were screened for prostrate, lung, colon and ovarian cancer over. Later standard clinical information on breast cancer was linked to these samples. Our plan was to first test samples collected 0-1 year before diagnosis of Stage I bc. If this were successful the study would be extended to samples collected even earlier before diagnosis. A second aim was to determine if IMS could be applied to DCIS and benign cancer. A third would be to follow the time course ofcancer in 30 of the PLCO subjects. In our first year almost all the effort was aimed at determining an IMS in the 0-1 yr PLCO samples. We could not do this. This was reported to the DoD panel. We assumed the samples were good and that it was the fault of the quality of the arrays we were using. The panel suspended funding and requested that we demonstrate the array quality was good and that we complete the analysis of the 0-1 year samples from PLCO before funding was resumed.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: